HK1249054A1 - 使用syk抑制劑對慢性移植物抗宿主病的治療 - Google Patents

使用syk抑制劑對慢性移植物抗宿主病的治療

Info

Publication number
HK1249054A1
HK1249054A1 HK18108940.4A HK18108940A HK1249054A1 HK 1249054 A1 HK1249054 A1 HK 1249054A1 HK 18108940 A HK18108940 A HK 18108940A HK 1249054 A1 HK1249054 A1 HK 1249054A1
Authority
HK
Hong Kong
Prior art keywords
treatment
host disease
versus host
graft versus
chronic graft
Prior art date
Application number
HK18108940.4A
Other languages
English (en)
Inventor
A Di Paolo Julie
Haw-Ling Lin Joseph
Lin Shao-Lee
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HK1249054A1 publication Critical patent/HK1249054A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18108940.4A 2015-04-21 2018-07-10 使用syk抑制劑對慢性移植物抗宿主病的治療 HK1249054A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562150691P 2015-04-21 2015-04-21
PCT/US2016/028303 WO2016172117A1 (en) 2015-04-21 2016-04-19 Treatment of chronic graft versus host disease with syk inhibitors

Publications (1)

Publication Number Publication Date
HK1249054A1 true HK1249054A1 (zh) 2018-10-26

Family

ID=55854820

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18104045.7A HK1244453A1 (zh) 2015-04-21 2018-03-23 使用syk抑制劑對慢性移植物抗宿主病的治療
HK18108940.4A HK1249054A1 (zh) 2015-04-21 2018-07-10 使用syk抑制劑對慢性移植物抗宿主病的治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18104045.7A HK1244453A1 (zh) 2015-04-21 2018-03-23 使用syk抑制劑對慢性移植物抗宿主病的治療

Country Status (14)

Country Link
US (1) US20160375019A1 (zh)
EP (1) EP3285808A1 (zh)
JP (1) JP2018513173A (zh)
KR (1) KR20170137200A (zh)
CN (1) CN107530354A (zh)
AU (1) AU2016252387A1 (zh)
BR (1) BR112017022323A2 (zh)
CA (1) CA2983611A1 (zh)
EA (1) EA201791946A1 (zh)
HK (2) HK1244453A1 (zh)
MX (1) MX2017013496A (zh)
SG (1) SG11201708075RA (zh)
TW (1) TW201711685A (zh)
WO (1) WO2016172117A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102307581B (zh) 2008-12-08 2016-08-17 吉利德康涅狄格股份有限公司 咪唑并哌嗪syk抑制剂
AU2011226689B2 (en) 2010-03-11 2016-09-01 Kronos Bio, Inc. Imidazopyridines Syk inhibitors
HUE052090T2 (hu) 2013-07-30 2021-04-28 Kronos Bio Inc A SYK inhibitorok polimorfja
EP3027601B1 (en) 2013-07-31 2017-10-25 Gilead Sciences, Inc. Syk inhibitors
PT3076976T (pt) 2013-12-04 2020-12-07 Kronos Bio Inc Métodos para tratar cancros
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
SG11201610551TA (en) 2014-07-14 2017-01-27 Gilead Sciences Inc Combinations for treating cancers
WO2017106564A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
CA3036384A1 (en) 2016-09-14 2018-03-22 Gilead Sciences, Inc. Syk inhibitors
CN110300764A (zh) * 2017-02-17 2019-10-01 Ose免疫疗法 抗SIRPg抗体的新用途
KR20220070056A (ko) 2017-08-25 2022-05-27 길리애드 사이언시즈, 인코포레이티드 Syk 억제제의 다형체
JP7162931B2 (ja) * 2018-07-17 2022-10-31 深▲チェン▼市塔吉瑞生物医薬有限公司 キナーゼ活性を阻害するためのアルキニル（ヘテロ）芳香族化合物
CA3130848A1 (en) 2019-02-22 2020-08-27 Kronos Bio, Inc. Solid forms of condensed pyrazines as syk inhibitors
CN112939983A (zh) * 2021-02-01 2021-06-11 暨明医药科技（苏州）有限公司 一种SYK激酶抑制剂Lanraplenib的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037900B2 (en) * 2001-10-12 2006-05-02 Supergen, Inc. Composition and method for treating graft-versus-host disease
SI2716157T1 (sl) * 2008-12-08 2016-10-28 Gilead Connecticut, Inc., c/o Gilead Sciences, Inc. Imidazopirazinski Syk-inhibitorji
US8450321B2 (en) * 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
AP2016009007A0 (en) 2013-07-30 2016-01-31 Gilead Connecticut Inc Formulation of syk inhibitors
HUE052090T2 (hu) 2013-07-30 2021-04-28 Kronos Bio Inc A SYK inhibitorok polimorfja
PT3076976T (pt) * 2013-12-04 2020-12-07 Kronos Bio Inc Métodos para tratar cancros
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
UY35898A (es) * 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.

Also Published As

Publication number Publication date
EP3285808A1 (en) 2018-02-28
KR20170137200A (ko) 2017-12-12
CN107530354A (zh) 2018-01-02
JP2018513173A (ja) 2018-05-24
EA201791946A1 (ru) 2018-03-30
US20160375019A1 (en) 2016-12-29
MX2017013496A (es) 2018-02-09
AU2016252387A1 (en) 2017-10-19
SG11201708075RA (en) 2017-11-29
HK1244453A1 (zh) 2018-08-10
WO2016172117A1 (en) 2016-10-27
TW201711685A (zh) 2017-04-01
BR112017022323A2 (pt) 2018-07-03
CA2983611A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
HK1249054A1 (zh) 使用syk抑制劑對慢性移植物抗宿主病的治療
HK1251409A1 (zh) 治療癌症的方法
ZA201804227B (en) Methods of treating cancer
IL253945A0 (en) kdm1a inhibitors to treat the disease
HK1254349A1 (zh) 用谷氨酰胺酶抑制劑治療肺癌
EP3122414A4 (en) Venous disease treatment
FI3851537T3 (fi) Hyperbilirubinemian hoito
IL278247B (en) mct4 inhibitors to treat the disease
ZA201706257B (en) Treatment of wood
EP3134436A4 (en) Treatment of h-ras-driven tumors
ZA201607740B (en) Treatment of the complications of chronic liver disease with caspase inhibitors
HK1253238A1 (zh) 用於治療疾病的gls1抑制劑
HK1258611A1 (zh) 腹水的治療
PT3164394T (pt) Inibidores gls1 para o tratamento de doenças
HK1252245A1 (zh) 用於治療癌症的核苷酸
EP3134528A4 (en) Multiple targeted rnai for the treatment of cancers
GB201408297D0 (en) Treatment of cancer
EP3313403A4 (en) TREATMENT OF CANCER WITH DNAPK INHIBITORS
GB201417456D0 (en) Treatment of cancer
EP3854402C0 (en) TREATMENT OR PREVENTION OF GRAFT-VERSE-HOST DISEASE
GB201512723D0 (en) Treatment of cancer
GB201507928D0 (en) Treatment of cancer
GB201504617D0 (en) Treatment of cancer
PT3851537T (pt) Tratamento da hiperbilirrubinemia
GB201504413D0 (en) Treatment of disease